Aman Chauhan MD, Kelley Chan MD, Thorvardur R. Halfdanarson MD, Andrew M. Bellizzi MD, Guido Rindi MD, PhD, Dermot O’Toole MD, Phillip S. Ge MD, Dhanpat Jain MD, Arvind Dasari MD, Daniel A. Anaya MD, MSHCT, Emily Bergsland MD, Erik Mittra MD, PhD, Alice C. Wei MD, Thomas A. Hope MD, Ayse T. Kendi MD, Samantha M. Thomas MS, Sherlonda Flem BS, CTR, James Brierley MB, Elliot A. Asare MD, MS, Kay Washington MD, PhD, Chanjuan Shi MD, PhD
{"title":"神经内分泌肿瘤的重要更新：第九版美国癌症联合委员会胃肠胰神经内分泌肿瘤分期系统","authors":"Aman Chauhan MD, Kelley Chan MD, Thorvardur R. Halfdanarson MD, Andrew M. Bellizzi MD, Guido Rindi MD, PhD, Dermot O’Toole MD, Phillip S. Ge MD, Dhanpat Jain MD, Arvind Dasari MD, Daniel A. Anaya MD, MSHCT, Emily Bergsland MD, Erik Mittra MD, PhD, Alice C. Wei MD, Thomas A. Hope MD, Ayse T. Kendi MD, Samantha M. Thomas MS, Sherlonda Flem BS, CTR, James Brierley MB, Elliot A. Asare MD, MS, Kay Washington MD, PhD, Chanjuan Shi MD, PhD","doi":"10.3322/caac.21840","DOIUrl":null,"url":null,"abstract":"<p>The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":null,"pages":null},"PeriodicalIF":503.1000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21840","citationCount":"0","resultStr":"{\"title\":\"Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors\",\"authors\":\"Aman Chauhan MD, Kelley Chan MD, Thorvardur R. Halfdanarson MD, Andrew M. Bellizzi MD, Guido Rindi MD, PhD, Dermot O’Toole MD, Phillip S. Ge MD, Dhanpat Jain MD, Arvind Dasari MD, Daniel A. Anaya MD, MSHCT, Emily Bergsland MD, Erik Mittra MD, PhD, Alice C. Wei MD, Thomas A. Hope MD, Ayse T. Kendi MD, Samantha M. Thomas MS, Sherlonda Flem BS, CTR, James Brierley MB, Elliot A. Asare MD, MS, Kay Washington MD, PhD, Chanjuan Shi MD, PhD\",\"doi\":\"10.3322/caac.21840\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.</p>\",\"PeriodicalId\":137,\"journal\":{\"name\":\"CA: A Cancer Journal for Clinicians\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":503.1000,\"publicationDate\":\"2024-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21840\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CA: A Cancer Journal for Clinicians\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.3322/caac.21840\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.3322/caac.21840","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
美国癌症联合委员会（AJCC）对包括胃肠胰神经内分泌肿瘤（GEP-NET）在内的所有癌症部位的分期系统都是动态的，需要定期更新以优化 AJCC 分期定义。这就需要专家们通力合作，负责评估支持每个分期系统变化的新证据。GEP-NET 是仅次于结直肠癌的第二大胃肠道肿瘤。自 AJCC 第八版出版以来，世界卫生组织更新了分类方法，将 3 级 GEP-NET 与分化不良的神经内分泌癌区分开来。此外，由于 GEP-NET 的诊断和治疗技术取得了重大进展，AJCC 第 9 版主张不使用血清嗜铬粒蛋白 A 诊断和监测 GEP-NET。此外，AJCC 第 9 版认识到内窥镜检查和内窥镜切除术在 NET 的诊断和治疗中发挥着越来越重要的作用，尤其是在胃、十二指肠和结直肠。最后，在这些疾病部位以及阑尾的 I 期中增加了 T1NXM0。
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.
期刊介绍：
CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
